89bio Ltd., a San Francisco-based startup focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, has closed a $60 million series A financing to advance an asset acquired from Israel's Teva Pharmaceutical Industries Ltd. through proof of concept. Currently in phase I testing, the long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue arrived at the company with positive preclinical data and an approved investigational new drug application.